Differential responses to 223Ra and Alpha-particles exposure in prostate cancer driven by mitotic catastrophe

Differential responses to 223Ra and Alpha-particles exposure in prostate cancer driven by mitotic catastrophe

IntroductionRadium-223 (223Ra) has been shown to have an overall survival benefit in metastatic castration-resistant prostate cancer (mCRPC) involving bone. Despite its increased clinical usage, relatively little is known regarding the mechanism of action of 223Ra at the cellular level.MethodsWe eva...

Full description

Bibliographic Details
Main Authors:	Francisco D. C. Guerra Liberal, Hugo Moreira, Kelly M. Redmond, Joe M. O’Sullivan, Ali H. D. Alshehri, Timothy C. Wright, Victoria L. Dunne, Caoimhghin Campfield, Sandra Biggart, Stephen J. McMahon, Kevin M. Prise
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Oncology
Subjects:	alpha particles radium-223 mitotic catastrophe radiation effects bone metastases
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.877302/full

Similar Items

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
by: Axel Heidenreich, et al.
Published: (2019-01-01)

Radium 223 dichloride for prostate cancer treatment
by: Deshayes E, et al.
Published: (2017-09-01)

Necroptosis as a Novel Facet of Mitotic Catastrophe
by: Aleksandra Yu. Egorshina, et al.
Published: (2022-03-01)

Feasibility study of radium-223 production in Tehran Research Reactor for treatment of bone metastases
by: Reza Bagheri, et al.
Published: (2016-02-01)

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment
by: Elisabet Cantó, et al.
Published: (2023-06-01)

A link between mitotic defects and mitotic catastrophe: detection and cell fate
by: Elena V. Sazonova, et al.
Published: (2021-12-01)

Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
by: Weronika Gawęda, et al.
Published: (2020-10-01)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
by: Monica Vidal, et al.

Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer
by: Joe M. O’Sullivan, et al.
Published: (2022-12-01)

MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells
by: Yi Na Yoon, et al.
Published: (2018-07-01)

Effect of Radium-223 on the Gut Microbiota of Prostate Cancer Patients: A Pilot Case Series Study
by: Ana Fernandes, et al.
Published: (2022-10-01)

POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Ocular complications with the use of radium-223: a case series
by: Julie R. Bloom, et al.
Published: (2022-05-01)

Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
by: Gayed I, et al.
Published: (2018-09-01)

DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer
by: Li-Wen Chiou, et al.
Published: (2023-06-01)

Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
by: Viviana Frantellizzi, et al.
Published: (2020-10-01)

Inhibition of the lncRNA MIAT prevents podocyte injury and mitotic catastrophe in diabetic nephropathy
by: Ziyang Wang, et al.
Published: (2022-06-01)

Bioinformatics Analysis Confirms the Target Protein Underlying Mitotic Catastrophe of 4T1 Cells under Combinatorial Treatment of PGV-1 and Galangin
by: Nurul Awali Fauziyah Hasbiyani, et al.
Published: (2021-08-01)

Estimation of the lower limits for feasible Ra-223 SPECT imaging: a Monte Carlo simulation study
by: Akihiko Takahashi, et al.
Published: (2021-07-01)

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
by: Tai-Lung Cha, et al.
Published: (2017-11-01)

The Curies’ element: state of the art and perspectives on the use of radium in nuclear medicine
by: Sara Franchi, et al.
Published: (2023-11-01)

[223Ra] RaCl2 nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era
by: Yang Yang, et al.
Published: (2022-12-01)

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
by: Masato Dobashi, et al.
Published: (2020-09-01)

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
by: Mari I. Suominen, et al.
Published: (2021-05-01)

Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Yasuo Oguma, et al.
Published: (2022-09-01)

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerResearch in context
by: Celestia S. Higano, et al.
Published: (2023-06-01)

Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice
by: Raniv D. Rojo, et al.
Published: (2021-01-01)

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT
by: Kalevi Kairemo, et al.
Published: (2015-10-01)

Biology of Glioblastoma Multiforme—Exploration of Mitotic Catastrophe as a Potential Treatment Modality
by: Barbora Vitovcova, et al.
Published: (2020-07-01)

Quantitative measurement of 219Rn radioactivity in exhaled breath from patients with bone metastasis of castration-resistant prostate cancer treated with 223RaCl2
by: Kazuhiro Ooe, et al.
Published: (2019-07-01)

Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report
by: Hélène Houssiau, et al.
Published: (2022-05-01)

Radium-223 for the treatment of patients with castration-resistant prostate cancer with bone metastases
by: A. D. Kaprin, et al.
Published: (2018-07-01)

MCDB: A comprehensive curated mitotic catastrophe database for retrieval, protein sequence alignment, and target prediction
by: Le Zhang, et al.
Published: (2021-10-01)

PSMA and 18F-FDG PET Imaging in the Treatment of Metastatic Prostate Cancer with 223Ra: Initial Application and Experience
by: HU Guilan, et al.
Published: (2023-07-01)

Study of <sup>211</sup>Bi and <sup>211</sup>Pb Recoils Release from <sup>223</sup>Ra Labelled TiO<sub>2</sub> Nanoparticles
by: Ján Kozempel, et al.
Published: (2022-12-01)

Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01)

Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 Dichloride
by: Kevin Kaulanjan, et al.
Published: (2022-09-01)

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
by: Hamza Hasan, et al.
Published: (2020-06-01)

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model
by: Mari I. Suominen, et al.
Published: (2023-01-01)

Hydroxyapatite and Titanium Dioxide Nanoparticles: Radiolabelling and In Vitro Stability of Prospective Theranostic Nanocarriers for <sup>223</sup>Ra and <sup>99m</sup>Tc
by: Petra Suchánková, et al.
Published: (2020-08-01)